Improvement in tardive dyskinesia after muscimol therapy.

Article date: 1979/5/1

PubMed ID: 35117

Journal name: Archives of general psychiatry (ISSN: 0003-990X)


Muscimol, thought to be a agonist of gamma-aminobutyric acid (GABA), was administered to eight neuroleptic-free subjects with tardive dyskinesia. At oral dose levels from 5 to 9 mg, involuntary movements were consistently attenuated, usually in the absence of sedation. These results support the view that pharmacologic attempts to stimulate GABA-mediated synaptic transmission may afford symptomatic relief to patients with tardive dyskinesia.

This document is available from: http://directlinks.cc/files/muscimol/35117.pdf

Author List: Tamminga C A, Crayton J W, Chase T N

Publication Types: Journal Article

Substances mentioned in the article: Antipsychotic Agents; Oxazoles; Receptors, Dopamine; Muscimol; gamma-Aminobutyric Acid; Dopamine;

Mesh terms: Adult; Aged; Antipsychotic Agents/adverse effects; Dopamine/physiology; Drug Evaluation; Dyskinesia, Drug-Induced/drug therapy; Extrapyramidal Tracts/drug effects; Female; Humans; Male; Middle Aged; Muscimol/pharmacology; Oxazoles/therapeutic use; Receptors, Dopamine/drug effects; Schizophrenia/drug therapy; Stimulation, Chemical; Synaptic Transmission/drug effects; gamma-Aminobutyric Acid/pharmacology;

35117.txt · Last modified: 2018/11/22 21:16 (external edit)